Impact of tumor volume on outcomes in patients with locally advanced non-small cell lung cancer receiving chemoradiotherapy and consolidation durvalumab
Puntos clave
This research aims to understand how tumor volume influences progression-free survival in lung cancer patients undergoing treatment.
Analyzed tumor volume as a prognostic factor for patient outcomes.
Evaluated progression-free survival as the primary outcome measure.
Utilized chemoradiotherapy and durvalumab as treatment protocols.
Tumor volume significantly correlates with progression-free survival.
Patients with smaller tumor volumes experience better outcomes.
Findings support the use of tumor volume in treatment planning and risk assessment.
Resumen
PTV emerged as an independent prognostic factor for PFS, suggesting its utility in risk stratification and individualized treatment planning.
Impact of tumor volume on outcomes in patients with locally advanced non-small cell lung cancer receiving chemoradiotherapy and consolidation durvalumab | Synapse